Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Branford

Showing results (71-80 of 136) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|July 24, 2023
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alphaYazad D Irani, Amy Hughes, Chung H Kok, et al.
Blood|March 21, 2012
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementSusan Branford, David T Yeung, Jodi A Prime, et al.
Blood|March 8, 2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
Blood Cancer Journal|April 21, 2022
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuationShady Adnan Awad, Oscar Brück, Naranie Shanmuganathan, et al.
International Journal of Clinical Oncology|October 12, 2011
Harmonization of molecular monitoring of chronic myeloid leukemia therapy in JapanChikashi Yoshida, Linda Fletcher, Kazuteru Ohashi, et al.
Leukemia|March 27, 2024
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?Hagop Kantarjian, Susan Branford, Massimo Breccia, et al.
Leukemia|February 21, 2020
Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemiaDaniel W Thomson, Nur Hezrin Shahrin, Paul P S Wang, et al.
The New England Journal of Medicine|October 10, 2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaTim P Hughes, Jaspal Kaeda, Susan Branford, et al.
Blood|September 26, 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMartin C Müller, Jorge E Cortes, Dong-Wook Kim, et al.
Blood|April 15, 2016
Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spotsOlga Sala Torra, Lan Beppu, Jordan L Smith, et al.
Pageof 14

Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|July 24, 2023
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alphaYazad D Irani, Amy Hughes, Chung H Kok, et al.
Blood|March 21, 2012
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementSusan Branford, David T Yeung, Jodi A Prime, et al.
Blood|March 8, 2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisSusan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
Blood Cancer Journal|April 21, 2022
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuationShady Adnan Awad, Oscar Brück, Naranie Shanmuganathan, et al.
International Journal of Clinical Oncology|October 12, 2011
Harmonization of molecular monitoring of chronic myeloid leukemia therapy in JapanChikashi Yoshida, Linda Fletcher, Kazuteru Ohashi, et al.
Leukemia|March 27, 2024
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?Hagop Kantarjian, Susan Branford, Massimo Breccia, et al.
Leukemia|February 21, 2020
Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemiaDaniel W Thomson, Nur Hezrin Shahrin, Paul P S Wang, et al.
The New England Journal of Medicine|October 10, 2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaTim P Hughes, Jaspal Kaeda, Susan Branford, et al.
Blood|September 26, 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMartin C Müller, Jorge E Cortes, Dong-Wook Kim, et al.
Blood|April 15, 2016
Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spotsOlga Sala Torra, Lan Beppu, Jordan L Smith, et al.
Pageof 14